Johnson & Johnson Net Change in Short-term Investments 2012-2026 | JNJ

Johnson & Johnson annual/quarterly net change in short-term investments history and growth rate from 2012 to 2026. Net change in short-term investments can be defined as the net cash flows from the sale and purchase of investments defined to be short-term, generally with maturities of less than one year from the purchase date.
  • Johnson & Johnson net change in short-term investments for the quarter ending March 31, 2026 was $0M, a 0% increase year-over-year.
  • Johnson & Johnson net change in short-term investments for the twelve months ending March 31, 2026 was $0M, a 0% increase year-over-year.
  • Johnson & Johnson annual net change in short-term investments for 2025 was $0B, a 0% decline from 2024.
  • Johnson & Johnson annual net change in short-term investments for 2024 was $0B, a 0% decline from 2023.
  • Johnson & Johnson annual net change in short-term investments for 2023 was $0B, a 0% decline from 2022.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Johnson & Johnson Annual Net Change in Short-term Investments
(Millions of US $)
2025 N/A
2024 N/A
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A
2014 N/A
2013 N/A
2012 N/A
2011 N/A
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $574.358B $94.193B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $887.629B 38.81
AbbVie (ABBV) United States $367.673B 20.79
Roche Holding AG (RHHBY) Switzerland $318.782B 0.00
Merck (MRK) United States $299.893B 13.54
Novartis AG (NVS) Switzerland $293.951B 17.16
Novo Nordisk (NVO) Denmark $167.527B 9.60
Pfizer (PFE) United States $153.074B 8.33
Sanofi (SNY) France $114.048B 10.56
Bayer (BAYRY) Germany $46.178B 8.70
Innoviva (INVA) United States $1.760B 5.88